The in vitro effect of new combinations of carbapenem-β-lactamase inhibitors for Mycobacterium abscessus.

ABSTRACT: As new treatment alternatives for Mycobacterium abscessus complex (MABC) are urgently needed, we determined the minimum inhibitory concentrations (MICs) for novel carbapenem combinations, including imipenem-relebactam and tebipenem-avibactam against 98 MABC isolates by broth microdilution. The MIC50 was reduced from 16 to 8 mg/L by adding relebactam to imipenem, while the addition of avibactam to tebipenem showed a more pronounced reduction from 256 to 16 mg/L, representing a promising non-toxic, oral treatment option for further exploration.

SUBMITTER: Froberg G 

PROVIDER: S-EPMC10583658 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature